TME Pharma Announces the End of the Convertible Debt Program With the Successful €1.48 Million Financing Intended for Buyback of All Outstanding Convertible Debt

BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces the successful closing of a €1.48 million gross private placement financing with a group of new investors. The proceeds will be used to repurchase all the outstanding convertible bonds held by Atlas Special Opportunities, LLC (ASO), thereby ending TME Pharma's conve